Table 3.
Average modified Magee recurrence score groups and associated Oncotype DX® risk categories from the validation population (n = 620) and original test population31 (n = 283)
| Average modified Magee score (amMs)a |
Oncotype DX® recurrence score Validation population |
Oncotype DX® recurrence score Original population |
||||||
|---|---|---|---|---|---|---|---|---|
| High | Intermediate | Low | %b | High | Intermediate | Low | %b | |
| amMs <9 | 0 | 0 | 4 | 100.0% | 0 | 0 | 5 | 100.0% |
| amMs ≤10 | 0 | 2 | 22 | 91.7% | 0 | 2 | 21 | 91.3% |
| amMs ≤11 | 0 | 7 | 45 | 86.5% | 0 | 5 | 31 | 86.1% |
| amMs ≤12 | 0 | 13 | 84 | 86.6% | 0 | 9 | 43 | 82.7% |
| amMs ≤14 | 0 | 22 | 125 | 85.0% | 0 | 12 | 61 | 83.6% |
| amMs ≤15 | 1 | 36 | 206 | 84.8% | 0 | 26 | 96 | 78.7% |
| amMs <18 | 1 | 63 | 261 | 80.3% | 0 | 42 | 116 | 73.4% |
| NS <6 and ER/PR ≥150 AND Ki67 <10% | 0 | 11 | 56 | 83.6% | 0 | 4 | 34 | 89.5% |
| amMs >30 | 17 | 0 | 0 | 100.0% | 8 | 0 | 0 | 100.0% |
a
Cases with an available Ki‐67.
b
Percent Oncotype DX® low risk except for amMs >30 which would be percent Oncotype DX® high risk.